Business
Global launch of clinical services laboratories
Global launch of clinical services laboratories.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8707T\n Angle PLC\n 30 March 2021\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 30 March 2021\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n GLOBAL LAUNCH OF CLINICAL SERVICES LABORATORIES\n \n \n \n \n \n Delivering on strategy to accelerate commercialisation of the Parsortix system and act as a demonstrator to support product deployment\n \n \n \n \n \n \n UK and US clinical laboratories now open and ready to provide \n \n \n CTC analysis services and discussions with pharmaceutical industry customers ongoing\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, \n is delighted to announce that it has completed the fitout and staffing of its clinical services laboratories in Guildford UK, and Plymouth Meeting PA, United States. This launch comes ahead of schedule with the US laboratory being completed sooner than anticipated and the UK laboratory opening in line with anticipated timescales. Together, these laboratories will allow ANGLE to accelerate the commercial deployment of the Parsortix® system by offering services to pharmaceutical and biotech customers for use in cancer drug clinical trials and, once the laboratories are accredited and tests validated, through the provision of Laboratory Developed Tests (LDTs) for patient care. \n \n \n \n \n \n ANGLE's sample to answer liquid biopsy solution via a simple blood test enables longitudinal monitoring of patients during drug trials (before, during and after drug intervention) which is not possible with tissue biopsy. This represents a significant market opportunity for ANGLE. In a single subset of this market, there are over 2,000 PD-L1/PD-1 interventional trials registered on clinicaltrials.gov, enrolling over 300,000 patients, which would be potential targets for ANGLE's pharma services business.\n \n \n \n \n \n ANGLE is targeting future clinical studies for adoption of the Parsortix system and has developed service capabilities in the United Kingdom and the United States to process samples on a commercial scale as part of global pharma trials. ANGLE has already established dialogue with prospective customers and collaborators for the deployment of CTC liquid biopsy analysis in cancer drug trials, with a number of these...